Incidencia de neumonía neumocócica y por cualquier causa en adultos en Cataluña tras la implementación de la vacunación antineumocócica universal en pediatría: 2015-2016 vs. 2017-2018

IF 2.5 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica Pub Date : 2025-08-01 DOI:10.1016/j.eimc.2025.01.011

Verònica Torras-Vives , Cinta de Diego-Cabanes , Eva M. Satué-Gracia , Maria José Forcadell-Peris , Olga Ochoa-Gondar , Ángel Vila-Córcoles

{"title":"Incidencia de neumonía neumocócica y por cualquier causa en adultos en Cataluña tras la implementación de la vacunación antineumocócica universal en pediatría: 2015-2016 vs. 2017-2018","authors":"Verònica Torras-Vives , Cinta de Diego-Cabanes , Eva M. Satué-Gracia , Maria José Forcadell-Peris , Olga Ochoa-Gondar , Ángel Vila-Córcoles","doi":"10.1016/j.eimc.2025.01.011","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>To analyze the incidence of pneumonia in adults following public funding of the 13-valent pneumococcal conjugate vaccine (PCV13) for children in Catalonia.</div></div><div><h3>Methods</h3><div>Two cohorts were analyzed: 2,025,730 individuals aged ≥50 years in 2015-2016 (pre-funding) and 2,059,645 in 2017-2018 (post-funding). Hospitalizations for pneumococcal pneumonia (PP) and all-cause pneumonia (ACP) were identified through the CMBD database across 68 Catalonian hospitals. Incidence rate ratios (IRR) between periods were estimated.</div></div><div><h3>Results</h3><div>PP incidence increased from 83.6/100,000 (2015-2016) to 90.7/100,000 (2017-2018) (IRR: 1.09; 95% <span>C</span>I: 1.03-1.14), while ACP decreased slightly from 617.9/100,000 to 609.7/100,000 (IRR: 0.99; 95% CI: 0.97-1.00). ACP reductions were significant in individuals aged 65-79, those with chronic lung disease, and men. PP increased significantly in those aged >80 years.</div></div><div><h3>Conclusion</h3><div>Adult hospitalized pneumonia incidence did not significantly decrease in the two years following PCV13 public funding for children.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 7","pages":"Pages 444-447"},"PeriodicalIF":2.5000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedades infecciosas y microbiologia clinica","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213005X2500028X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

To analyze the incidence of pneumonia in adults following public funding of the 13-valent pneumococcal conjugate vaccine (PCV13) for children in Catalonia.

Methods

Two cohorts were analyzed: 2,025,730 individuals aged ≥50 years in 2015-2016 (pre-funding) and 2,059,645 in 2017-2018 (post-funding). Hospitalizations for pneumococcal pneumonia (PP) and all-cause pneumonia (ACP) were identified through the CMBD database across 68 Catalonian hospitals. Incidence rate ratios (IRR) between periods were estimated.

Results

PP incidence increased from 83.6/100,000 (2015-2016) to 90.7/100,000 (2017-2018) (IRR: 1.09; 95% CI: 1.03-1.14), while ACP decreased slightly from 617.9/100,000 to 609.7/100,000 (IRR: 0.99; 95% CI: 0.97-1.00). ACP reductions were significant in individuals aged 65-79, those with chronic lung disease, and men. PP increased significantly in those aged >80 years.

Conclusion

Adult hospitalized pneumonia incidence did not significantly decrease in the two years following PCV13 public funding for children.

查看原文本刊更多论文

在儿科实施普遍肺炎球菌疫苗接种后，加泰罗尼亚成人肺炎球菌和任何原因肺炎的发病率：2015-2016年vs. 2017-2018年

目的：分析加泰罗尼亚儿童13价肺炎球菌结合疫苗（PCV13）公共资助后成人肺炎的发病率。方法分析两个队列：2015-2016年（资助前）2025730名年龄≥50岁的个体和2017-2018年（资助后）2059645名个体。通过加泰罗尼亚68家医院的CMBD数据库确定了肺炎球菌肺炎（PP）和全因肺炎（ACP）的住院情况。估计不同时期的发病率比（IRR）。结果spp发病率由2015-2016年的83.6/10万上升至2017-2018年的90.7/10万(IRR: 1.09；95% CI: 1.03-1.14)，而ACP从617.9/100,000略微下降至609.7/100,000 (IRR: 0.99；95% ci: 0.97-1.00)。ACP在65-79岁、慢性肺病患者和男性中显著降低。PP在80岁时显著升高。结论儿童PCV13公共资助后2年内成人住院肺炎发病率无明显下降。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Enfermedades infecciosas y microbiologia clinica 医学-传染病学

CiteScore

2.10

自引率

8.00%

发文量

194

审稿时长

29 days

期刊介绍： Hoy está universalmente reconocida la renovada y creciente importancia de la patología infecciosa: aparición de nuevos agentes patógenos, de cepas resistentes, de procesos con expresión clínica hasta ahora desconocida, de cuadros de una gran complejidad. Paralelamente, la Microbiología y la Infectología Clínicas han experimentado un gran desarrollo como respuesta al reto planteado por la actual patología infecciosa. Enfermedades Infecciosas y Microbiología Clínica es la Publicación Oficial de la Sociedad Española SEIMC. Cumple con la garantía científica de esta Sociedad, la doble función de difundir trabajos de investigación, tanto clínicos como microbiológicos, referidos a la patología infecciosa, y contribuye a la formación continuada de los interesados en aquella patología mediante artículos orientados a ese fin y elaborados por autores de la mayor calificación invitados por la revista.